Table 3.
Anthropometric and blood chemistry analysis of 12-week treatment (COEC) and control (placebo) group.
| Treatment Group (n = 36) | Control Group (n = 40) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 Week | 12 Weeks | Change from Baseline (12 Week–0 Week) |
p-Value ** | 0 Week | 12 Weeks | Change from Baseline (12 Week–0 Week) |
p-Value ** |
p-Value $ (12 Week) |
|
| Anthropometric | |||||||||
| Body weight (kg) | 68.09 ± 5.99 | 66.87 ± 6.13 | −1.22 ± 2.14 | 0.001 | 68.45 ± 6.54 | 67.50 ± 6.77 | −0.94 ± 1.59 | 0.001 | 0.516 |
| Waist circumference (cm) | 91.05 ± 5.73 | 89.00 ± 5.35 | −2.05 ± 2.89 | 0.001 | 91.68 ± 6.04 | 89.70 ± 5.60 | −1.98 ± 2.22 | 0.001 | 0.752 |
| Hip circumference (cm) | 100.18 ± 4.54 | 98.79 ± 4.01 | −1.39 ± 1.94 | 0.001 | 101.59 ± 4.15 | 100.45 ± 4.27 | −1.14 ± 1.61 | 0.001 | 0.281 |
| Waist-to-hip ratio | 0.91 ± 0.04 | 0.90 ± 0.04 | −0.01 ± 0.02 | 0.046 | 0.90 ± 0.05 | 0.89 ± 0.05 | −0.01 ± 0.02 | 0.010 | 0.687 |
| BMI (kg/m2) | 27.01 ± 1.55 | 26.52 ± 1.73 | −0.49 ± 0.83 | 0.001 | 27.51 ± 1.30 | 27.12 ± 1.45 | −0.39 ± 0.64 | 0.001 | 0.537 |
| Blood chemistry | |||||||||
| Total cholesterol (mg/dL) | 205.42 ± 32.69 | 208.86 ± 30.61 | 3.44 ± 22.84 | 0.371 | 203.48 ± 33.21 | 212.63 ± 34.91 | 9.15 ± 23.58 | 0.018 | 0.302 |
| HDL-Cholesterol (mg/dL) | 56.19 ± 9.80 | 56.83 ± 11.47 | 0.64 ± 7.63 | 0.618 | 55.83 ± 13.25 | 55.43 ± 10.47 | −0.40 ± 8.32 | 0.762 | 0.492 |
| LDL-Cholesterol (mg/dL) | 125.50 ± 28.16 | 131.14 ± 26.64 | 5.64 ± 19.82 | 0.096 | 119.68 ± 30.68 | 131.35 ± 32.50 | 11.68 ± 27.37 | 0.010 | 0.421 |
| Triglyceride (mg/dL) | 118.44 ± 82.06 | 104.47 ± 51.37 | −13.97 ± 50.40 | 0.105 | 139.83 ± 101.64 | 129.08 ± 99.05 | −10.75 ± 103.16 | 0.513 | 0.357 |
| Adiponectin (μg/mL) | 8.10 ± 3.47 | 8.33 ± 2.90 | 0.23 ± 2.80 | 0.619 | 7.84 ± 3.26 | 7.89 ± 2.82 | 0.05 ± 1.61 | 0.852 | 0.527 |
**: Compared within groups; p-value for paired t-test. $: Compared between groups; p-value for ANCOVA adjusted baseline.